Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2012 1
2013 2
2014 3
2015 3
2016 1
2018 1
2020 1
2021 5
2022 7
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Early Discontinuation, Results Reporting, and Publication of Gynecology Clinical Trials From 2007 to 2020.
Steinberg JR, Magnani CJ, Turner BE, Weeks BT, Young AMP, Lu CF, Zhang N, Richardson MT, Fitzgerald AC, Mekonnen Z, Redman T, Adetunji M, Martin SA, Anderson JN, Chan KS, Milad MP. Steinberg JR, et al. Among authors: fitzgerald ac. Obstet Gynecol. 2022 May 1;139(5):821-831. doi: 10.1097/AOG.0000000000004735. Epub 2022 Apr 5. Obstet Gynecol. 2022. PMID: 35576341
Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
Ibrahim SF, Kasprzak JM, Hall MA, Fitzgerald AL, Siegel JJ, Kurley SJ, Covington KR, Goldberg MS, Farberg AS, Trotter SC, Reed K, Brodland DG, Koyfman SA, Somani AK, Arron ST, Wysong A. Ibrahim SF, et al. Among authors: fitzgerald al. Future Oncol. 2022 Mar;18(7):833-847. doi: 10.2217/fon-2021-1277. Epub 2021 Nov 25. Future Oncol. 2022. PMID: 34821148 Free article.
Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
Hooper PB, Farberg AS, Fitzgerald AL, Siegel JJ, Rackley BB, Prasai A, Kurley SJ, Goldberg MS, Litchman GH. Hooper PB, et al. Among authors: fitzgerald al. Cancer Invest. 2022 Nov;40(10):911-922. doi: 10.1080/07357907.2022.2116454. Epub 2022 Sep 15. Cancer Invest. 2022. PMID: 36073945
Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients.
Borman S, Wilkinson J, Meldi-Sholl L, Johnson C, Carter K, Covington KR, Fitzgerald AL, Kurley SJ, Farberg AS, Goldberg MS, Monzon FA, Oelschlager K, Cook RW. Borman S, et al. Among authors: fitzgerald al. Diagn Pathol. 2022 Feb 25;17(1):32. doi: 10.1186/s13000-022-01211-w. Diagn Pathol. 2022. PMID: 35216597 Free PMC article.
Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series.
Au JH, Hooper PB, Fitzgerald AL, Somani AK. Au JH, et al. Among authors: fitzgerald al. Dermatol Ther (Heidelb). 2022 Feb;12(2):591-597. doi: 10.1007/s13555-021-00665-y. Epub 2021 Dec 23. Dermatol Ther (Heidelb). 2022. PMID: 34951694 Free PMC article.
24 results